

## DAFTAR PUSTAKA

- Aaron, S.D., Vandemheen, K.L., Fergusson, D., Maltais, F., Bourbeau, J., Goldstein, R., Balter, M., O'Donnell, D., McIvor, A., Sharma, S., Bishop, G., Anthony, J., Cowie, R., Field, S., Hirsch, A., Hernandez, P., Rivington, R., Road, J., Hoffstein, V. dan Hodder, R. (2007). Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone–Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease. *Annals of Internal Medicine*, 146(8), p.545. doi:<https://doi.org/10.7326/0003-4819-146-8-200704170-00152>.
- Adams, B.S. dan Nguyen, H. (2020). *Salmeterol*. [online] PubMed. Diakses melalui : <https://www.ncbi.nlm.nih.gov/books/NBK557453/>.
- Agarwal, A.K., Raja, A. dan Brown, B.D. (2023). Chronic obstructive pulmonary disease (COPD). [online] National Library of Medicine. Diakses melalui : <https://www.ncbi.nlm.nih.gov/books/NBK559281/>.
- Aggarwal, B., Jones, P.W., Yunus, F., Lan, L.T.T., Boonsawat, W., Ismaila, A. dan Asciglu, S. (2021). Direct healthcare costs associated with management of asthma: comparison of two treatment regimens in Indonesia, Thailand and Vietnam. *Journal of Asthma*, 59(6), pp.1213–1220. doi:<https://doi.org/10.1080/02770903.2021.1903915>.
- Alvarado-Gonzalez, A. dan Arce, I. (2015). Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma. *Journal of Clinical Medicine Research*, 7(11), pp.831–839. doi:<https://doi.org/10.14740/jocmr2305w>.
- Ambianti, N., Andayani, T.A., dan Sulistiawaty, E. (2019). Analisis biaya penyakit Diabetes Melitus sebagai pertimbangan perencanaan pembiayaan kesehatan. *Jurnal Farmasi Galenika*; 5(1), 73 – 83.

- American Thoracic Society Statement. (2003). *American Journal of Respiratory and Critical Care Medicine*, 167(5), pp.787–797. doi:<https://doi.org/10.1164/rccm.167.5.787>.
- American Thoracic Society/European Respiratory Society Statement. (2003). *American Journal of Respiratory and Critical Care Medicine*, 168(7), pp.818–900. doi:<https://doi.org/10.1164/rccm.168.7.818>.
- Antus, B. (2013). Pharmacotherapy of Chronic Obstructive Pulmonary Disease: A Clinical Review. *ISRN Pulmonology*, [online] 2013, pp.1–11. doi:<https://doi.org/10.1155/2013/582807>
- Arifin, W.N. (2013). Introduction to sample size calculation. *Education in Medicine Journal*, 5(2). doi:<https://doi.org/10.5959/eimj.v5i2.130>.
- Aryal, S., Diaz-Guzman, E. and Mannino, D.M. (2013). COPD and gender differences: an update. *Translational Research*, 162(4), pp.208–218. doi:<https://doi.org/10.1016/j.trsl.2013.04.003>.
- Azeem, A.E-A., Hamdy, G., Amin, M. dan Rashad, A. (2013). Pulmonary function changes in diabetic lung. *Egyptian Journal of Chest Diseases and Tuberculosis*, [online] 62(3), pp.513–517. doi:<https://doi.org/10.1016/j.ejcdt.2013.07.006>.
- Balmes J, Becklake M, Blanc P, Henneberger P, Kreiss K, dan Mapp C. (2003). *American Journal of Respiratory and Critical Care Medicine*, 167(5), pp.787–797. doi:<https://doi.org/10.1164/rccm.167.5.787>.
- Barnes, P.J. (2010). Inhaled Corticosteroids. *Pharmaceuticals*, [online] 3(3), pp.514–540. doi:<https://doi.org/10.3390/ph3030514>.
- Blanchette, C.M., Dalal, A.A. dan Mapel, D. (2012). Changes in COPD demographics and costs over 20 years. *Journal of Medical Economics*, 15(6), pp.1176–1182. doi:<https://doi.org/10.3111/13696998.2012.713880>.

- Bollmeier, S.G. dan Hartmann, A.P. (2020). Management of chronic obstructive pulmonary disease: A review focusing on exacerbations. *American Journal of Health-System Pharmacy*, 77(4). doi:<https://doi.org/10.1093/ajhp/zxz306>.
- Bourbeau, J., Doiron, D., Biswas, S., Smith, B.M., Benedetti, A., Brook, J.R., Aaron, S.D., Chapman, K.R., Hernandez, P., Maltais, F., Marciniuk, D.D., O'Donnell, D., Sin, D.D., Walker, B., Dsilva, L., Nadeau, G., Coats, V., Compton, C., Miller, B.E. dan Tan, W.C. (2022). Ambient Air Pollution and Dysanapsis: Associations with Lung Function and COPD in the CanCOLD Study. *American Journal of Respiratory and Critical Care Medicine*. doi:<https://doi.org/10.1164/rccm.202106-1439oc>.
- Brazier, J., Ara, R., Azzabi, I., Busschbach, J., Chevrou-Séverac, H., Crawford, B., Cruz, L., Karnon, J., Lloyd, A., Paisley, S. dan Pickard, A.S. (2019). Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report. *Value in Health*, 22(3), pp.267–275. doi:<https://doi.org/10.1016/j.jval.2019.01.004>.
- Brode, S.K., Ling, S.C. dan Chapman, K.R. (2012). Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease. *Canadian Medical Association Journal*, [online] 184(12), pp.1365–1371. doi:<https://doi.org/10.1503/cmaj.111749>.
- Bulsara, K.G. dan Makaryus, A.N. (2020). *Candesartan*. [online] PubMed. Diakses melalui : <https://www.ncbi.nlm.nih.gov/books/NBK519501/>.
- Calverley, P.M.A., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W., Yates, J.C. dan Vestbo, J. (2007). Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. *New England Journal of Medicine*, 356(8), pp.775–789. doi:<https://doi.org/10.1056/nejmoa063070>.

- Calzetta, L., Ritondo, B.L., Matera, M.G., Cazzola, M. dan Rogliani, P. (2020). Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. *Expert Review of Respiratory Medicine*, 14(6), pp.621–635. doi:<https://doi.org/10.1080/17476348.2020.1743180>.
- Cazzola, M. dan Tashkin, D.P. (2009). Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. *COPD*, [online] 6(5), pp.404–415. doi:<https://doi.org/10.1080/15412550903156333>.
- Cazzola, M., Page, C.P., Calzetta, L. dan Matera, M.G. (2012). Pharmacology and Therapeutics of Bronchodilators. *Pharmacological Reviews*, 64(3), pp.450–504. doi:<https://doi.org/10.1124/pr.111.004580>.
- CDC (2019). *COPD Costs*. [online] Diakses melalui: <https://www.cdc.gov/copd/infographics/copd-costs.html>.
- Chatila, W.M., Thomashow, B.M., Minai, O.A., Criner, G.J. dan Make, B.J. (2008). Comorbidities in Chronic Obstructive Pulmonary Disease. *Proceedings of the American Thoracic Society*, [online] 5(4), pp.549–555. doi:<https://doi.org/10.1513/pats.200709-148et>.
- COPD Assessment Test (2022). *Chronic Obstructive Pulmonary Disease User Guide*, GlaxoSmithKline, United Kingdom.
- Dalal, A., Liu dan Riedel, A. (2010). Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009. *International Journal of Chronic Obstructive Pulmonary Disease*, p.533. doi:<https://doi.org/10.2147/copd.s24591>.
- Dalal A., St Charles M., Petersen H.V., Roberts M.H., Blanchette C.M., dan Manavi-Zieverink K. (2010). Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 µg versus salmeterol in severe COPD patients. *International Journal of Chronic Obstructive Pulmonary Disease*, p.179. doi:<https://doi.org/10.2147/copd.s10988>

De Matteis, S., Jarvis, D., Darnton, A., Hutchings, S., Sadhra, S., Fishwick, D., Rushton, L. dan Cullinan, P. (2019). The occupations at increased risk of COPD: analysis of lifetime job-histories in the population-based UK Biobank Cohort. *European Respiratory Journal*, [online] 54(1), p.1900186. doi:<https://doi.org/10.1183/13993003.00186-2019>.

De Miguel-Díez, J., Chancafe Morgan, J. dan Jimenez-Garcia, R. (2013). The association between COPD and heart failure risk: A review. *International Journal of Chronic Obstructive Pulmonary Disease*, [online] 8, p.305. doi:<https://doi.org/10.2147/copd.s31236>.

Diagnosis of Diseases of Chronic Airflow Limitation: Asthma COPD and Asthma -COPD Overlap Syndrome (ACOS) Based on the Global Strategy for Asthma Management and Prevention and the Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2014. (n.d.). Dapat diakses: [https://ginasthma.org/wp-content/uploads/2019/11/GINA\\_GOLD\\_ACOS\\_2014-wms.pdf](https://ginasthma.org/wp-content/uploads/2019/11/GINA_GOLD_ACOS_2014-wms.pdf). Dolovich, M.B., Ahrens, R.C., Hess, D.R., Anderson, P., Dhand, R., Rau, J.L., Smaldone, G.C., Guyatt, G., American College of Chest Physicians and American College of Asthma, Allergy, and Immunology (2005). Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest*, [online] 127(1), pp.335–371. doi:<https://doi.org/10.1378/chest.127.1.335>.

DiPiro, J.T., Talbert, R.L., Yee, G.C., Wells, B.G. dan L. Michael Posey (2020). *Pharmacotherapy A Pathophysiologic Approach 11/E*. McGraw Hill Professional.

Drummond, M., Wise, R., Hansel, N. dan Putcha, N. (2015). Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management. *Seminars in Respiratory and Critical Care*

*Medicine*, [online] 36(04), pp.575–591. doi:<https://doi.org/10.1055/s-0035-1556063>

Feng, J., Ding, G., Xie, Y., Zhao, D. dan Wang, X. (2018). Efficacy of budesonide/formoterol and tiotropium combination for the treatment of Chinese patients with chronic obstructive pulmonary disease. *Medicine*, 97(22), p.e10841. doi:<https://doi.org/10.1097/md.00000000000010841>.

Ferguson, G.T., Tashkin, D. P., Skärby, T., Jorup, C., Sandin, K., Greenwood, M., Pemberton, K., dan Trudo, F., Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. (2017). *Respiratory Medicine*, [online] 132, pp.31–41. doi:<https://doi.org/10.1016/j.rmed.2017.09.002>.

Ferguson, G.T. dan Make, B. (2023). *Stable COPD: Initial pharmacologic management*. [online] diakses dari : <https://medilib.ir/uptodate/show/1447#top> pada Februari 2024.

Getahun, B. dan Bekel, A.A. (2021). Work - Related Chronic Obstructive Pulmonary Disease. [online] [www.intechopen.com](http://www.intechopen.com). IntechOpen. Diakses melalui : <https://www.intechopen.com/chapters/76162>.

Giusman, R., dan Nurwahyuni, A. (2022). BIAYA PENGOBATAN PASIEN RAWAT INAP COVID-19 DI RUMAH SAKIT X TAHUN 2021. *Jurnal ekonomi kesehatan Indonesia*, 7(2), pp.96–96. doi:<https://doi.org/10.7454/eki.v7i2.5797>.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2018). *Global Strategy for the Diagnosis, Management, and Prevention of COPD (2018 Report)*. Diakses dari : <http://www.goldcopd.org>, diakses pada September 2023.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2019). *Global Strategy for the Diagnosis, Management, and Prevention of COPD (2019 Report)*. Diakses dari : <http://www.goldcopd.org>, diakses pada September 2023.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2022). *Global Strategy for the Diagnosis, Management, and Prevention of COPD (2022 Report)*. Diakses dari : <http://www.goldcopd.org>, diakses pada September 2023.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2023). *Global Strategy for the Diagnosis, Management, and Prevention of COPD (2023 Report)*. Diakses dari : <http://www.goldcopd.org>, diakses pada September 2023.

Gredic, M., Blanco, I., Kovacs, G., Helyes, Z., Ferdinandy, P., Olschewski, H., Barberà, J.A. dan Weissmann, N. (2020). Pulmonary hypertension in chronic obstructive pulmonary disease. *British Journal of Pharmacology*, 178(1), pp.132–151. doi:<https://doi.org/10.1111/bph.14979>.

Gupta, D., Agarwal, R., Aggarwal, A., Maturu, V., Dhooria, S., Prasad, K., Sehgal, I., Yenge, L., Jindal, A., Singh, N., Ghoshal, A., Khilnani, G., Samaria, J., Gaur, S., Behera, D. and Jindal, S. (2013). Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. *Lung India*, 30(3), p.228. doi:<https://doi.org/10.4103/0970-2113.116248>.

Gupta, R. dan Wadhwa, R. (2021). *Mucolytic Medications*. [online] PubMed. Diakses melalui: <https://www.ncbi.nlm.nih.gov/books/NBK559163/>.

Gutiérrez Villegas, C., Paz-Zulueta, M., Herrero-Montes, M., Parás-Bravo, P. dan Madrazo Pérez, M. (2021). Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review. *Health Economics Review*, 11(1). doi:<https://doi.org/10.1186/s13561-021-00329-9>.



- Halpin, D.M. (2008). Symbicort: a pharmacoeconomic review. *Journal of Medical Economics*, 11(2), pp.345–362. doi:<https://doi.org/10.3111/13696990802210984>.
- Han, M.K. (2020). Chronic Obstructive Pulmonary Disease in Women: A Biologically Focused Review with a Systematic Search Strategy. *International Journal of Chronic Obstructive Pulmonary Disease*, Volume 15, pp.711–721. doi:<https://doi.org/10.2147/copd.s237228>.
- Hawkins, N.M., Virani, S. dan Ceconi, C. (2013). Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. *European Heart Journal*, [online] 34(36), pp.2795–2807. doi:<https://doi.org/10.1093/eurheartj/eh192>.
- Heo, Y.-A. (2021). Budesonide/Glycopyrronium/Formoterol: A Review in COPD. *Drugs*, 81(12), pp.1411–1422. doi:<https://doi.org/10.1007/s40265-021-01562-6>.
- Huang, C., Kuo, S., Lin, L. dan Yang, Y. (2023). The efficacy of *N*-acetylcysteine in chronic obstructive pulmonary disease patients: a meta-analysis. *Therapeutic Advances in Respiratory Disease*, 17, p.175346662311585. doi:<https://doi.org/10.1177/17534666231158563>.
- Huang, W.-C., Tsai, Y.-H., Wei, Y.-F., Kuo, P.-H., Tao, C.-W., Cheng, S.-L., Lee, C.-H., Wu, Y.-K., Chen, N.-H., Hsu, W.-H., Hsu, J.-Y., Wang, C.-C. dan Lin, M.-S. (2015). Wheezing, a significant clinical phenotype of COPD: experience from the Taiwan Obstructive Lung Disease Study. *International Journal of Chronic Obstructive Pulmonary Disease*, [online] p.2121. doi:<https://doi.org/10.2147/copd.s92062>.
- Huber, M.B., Wacker, M.E., Vogelmeier, C.F. dan Leidl, R. (2015). Excess Costs of Comorbidities in Chronic Obstructive Pulmonary Disease: A Systematic



Review. *PLOS ONE*, 10(4), p.e0123292.  
doi:<https://doi.org/10.1371/journal.pone.0123292>.

Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A.H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., Mauskopf, J., Mullins, C.D., Petrou, S., Pwu, R.-F. dan Staniszewska, S. (2022). Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. *BMC Medicine*, 20(1). doi:<https://doi.org/10.1186/s12916-021-02204-0>.

Iheanacho, I., Zhang, S., King, D., Rizzo, M. dan Ismaila, A.S. (2020). Economic burden of Chronic Obstructive Pulmonary Disease (COPD): A systematic literature review. *International Journal of Chronic Obstructive Pulmonary Disease*, Volume 15, pp.439–460. doi:<https://doi.org/10.2147/copd.s234942>.

Jenkins, C.R., Postma, D.S., Anzueto, A.R., Make, B.J., Peterson, S., Eriksson, G. dan Calverley, P.M. (2015). Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. *BMC Pulmonary Medicine*, 15(1). doi:<https://doi.org/10.1186/s12890-015-0077-0>.

Johns, D.P., Walters, J.A.E. dan Walters, E.H. (2014). Diagnosis and early detection of COPD using spirometry. *Journal of thoracic disease*, [online] 6(11), pp.1557–69. doi:<https://doi.org/10.3978/j.issn.2072-1439.2014.08.18>.

Jones, P.W., Nadeau, G., Small, M. dan Adamek, L. (2014). Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations. *Respiratory Medicine*, 108(1), pp.129–135. doi:<https://doi.org/10.1016/j.rmed.2013.08.015>.

Kalola, U.K. dan Ambati, S. (2023). *Budesonide*. [online] PubMed. Diakses melalui : <https://www.ncbi.nlm.nih.gov/books/NBK563201/>.

- Kementerian Kesehatan Republik Indonesia (Kemenkes RI). (2013). Pedoman Penerapan Kajian Farmakoekonomi, 1-3. Kementerian Kesehatan Republik Indonesia. Jakarta.
- Kementerian Kesehatan Republik Indonesia (Kemenkes RI). (2019). *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Penyakit Paru Obstruktif Kronik*. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/687/2019.
- Kim, C., Kim, Y., Yang, D.-W., Rhee, C.K., Kim, S.K., Hwang, Y.-I., Park, Y.B., Lee, Y.M., Jin, S., Park, J., Hahm, C.-R., Park, C.-H., Park, S.Y., Jung, C.K., Kim, Y.-I., Lee, S.H., Yoon, H.K., Lee, J.H., Lim, S.Y. and Yoo, K.H. (2019). Direct and Indirect Costs of Chronic Obstructive Pulmonary Disease in Korea. *Tuberculosis and Respiratory Diseases*, 82(1), p.27. doi:<https://doi.org/10.4046/trd.2018.0035>.
- King, P.T. (2015). Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. *Clinical and Translational Medicine*, 4(1). doi:<https://doi.org/10.1186/s40169-015-0068-z>.
- Koo, H.-K., Park, S.-W., Park, J.-W., Choi, H.S., Kim, T.-H., Yoon, H.K., Yoo, K.H., Jung, K.-S., dan Kim, D.K. (2018). Chronic cough as a novel phenotype of chronic obstructive pulmonary disease. *International Journal of Chronic Obstructive Pulmonary Disease*, Volume 13, pp.1793–1801. doi:<https://doi.org/10.2147/copd.s153821>.
- Koarai, A., Yamada, M., Ichikawa, T., Fujino, N., Kawayama, T., dan Sugiura, H. (2021). Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis. *Respiratory Research*, 22(1). doi:<https://doi.org/10.1186/s12931-021-01777-x>.
- Lange, P. (2009). Chronic obstructive pulmonary disease and risk of infection. *Pneumonologia I Alergologia Polska*, [online] 77(3), pp.284–288. Diakses melalui : <https://pubmed.ncbi.nlm.nih.gov/19591100/>.

- Li, Y., Wu, W., Wang, X. dan Chen, L. (2022). Effect of Endurance Training in COPD Patients Undergoing Pulmonary Rehabilitation: A Meta-Analysis. *Computational and Mathematical Methods in Medicine*, [online] 2022, pp.1–7. doi:<https://doi.org/10.1155/2022/4671419>.
- Lin, J.Y., Li, Y., Tian, H., Goodman, M.J., Gabriel, S.A., Nazareth, T., Turner, S., Arcona, S., dan Kahler, K.H. (2014). Costs and health care resource utilization among chronic obstructive pulmonary disease patients with newly acquired pneumonia. *ClinicoEconomics and Outcomes Research*, [online] pp.349–349. doi:<https://doi.org/10.2147/ceor.s65824>.
- Liu, Y., Carlson, S.A., Watson, K.B., Xu, F., dan Greenlund, K. J. (2023). Trends in the Prevalence of Chronic Obstructive Pulmonary Disease Among Adults Aged  $\geq 18$  Years — United States, 2011–2021. *MMWR. Morbidity and Mortality Weekly Report*, [online] 72. doi:<https://doi.org/10.15585/mmwr.mm7246a1>.
- Lorensia, A., Monica Dyah Puspitasari, Soedarsono Soedarsono, dan Rivan Virlando Suryadinata (2022). Cost-Effectiveness Analysis of Budesonide/Formoterol and Fluticasone/Salmeterol for Stable Chronic Obstructive Lung Disease. *Jurnal respirologi Indonesia*, 42(4). doi:<https://doi.org/10.36497/jri.v42i4.378>.
- Lu, Y., Wang, X. dan Zhao, J. (2021). Effects of azithromycin on treating chronic obstructive pulmonary disease with acute exacerbation of chronic bronchitis in the stable phase. *American Journal of Translational Research*, 13(6), pp.7370–7375.
- MacNee, W. (2016). Is Chronic Obstructive Pulmonary Disease an Accelerated Aging Disease? *Annals of the American Thoracic Society*, [online] 13(Supplement\_5), pp.S429–S437. doi:<https://doi.org/10.1513/annalsats.201602-124aw>.

- Maleki-Yazdi, M.R., Kelly, S.M., Lam, S.S., Marin, M., Barbeau, M., dan Walker, V. (2012). The Burden of Illness in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease in Canada. *Canadian Respiratory Journal*, 19(5), pp.319–324. doi:<https://doi.org/10.1155/2012/328460>.
- Marques, L. dan Vale, N. (2022). Salbutamol in the Management of Asthma: a Review. *International Journal of Molecular Sciences*, [online] 23(22), p.14207. doi:<https://doi.org/10.3390/ijms232214207>.
- Martini, K. dan Frauenfelder, T. (2018). Emphysema and lung volume reduction: the role of radiology. *Journal of Thoracic Disease*, 10(S23), pp.S2719–S2731. doi:<https://doi.org/10.21037/jtd.2018.05.117>
- Menn, P., Heinrich, J., Huber, R.M., Jörres, R.A., John, J., Karrasch, S., Peters, A., Schulz, H. dan Holle, R. (2012). Direct medical costs of COPD – An excess cost approach based on two population-based studies. *Respiratory Medicine*, 106(4), pp.540–548. doi:<https://doi.org/10.1016/j.rmed.2011.10.013>.
- Michaux, K.D., Metcalfe, R.K., Burns, P., Conklin, A., Hoens, A.M., Smith, D., Struik, L., Safari, A., Sin, D.D., Mohsen Sadatsafavi, Bansback, N., Barn, P., Bottorff, J.L., Bryan, S., Carlsten, C., Mary De Vera, Gershon, A.S., Gupta, S., Gustafson, P. dan Mehrshad Mokhtaran. (2023). Implementing Predictive Analytics towards efficient COPD Treatments (IMPACT): protocol for a stepped-wedge cluster randomized impact study. *Diagnostic and prognostic research*, [online] 7(1). doi:<https://doi.org/10.1186/s41512-023-00140-6>.
- Montuschi, P. (2006). Pharmacological treatment of chronic obstructive pulmonary disease. *International Journal of COPD*, 1(4), pp.409–423. doi:<https://doi.org/10.2147/copd.2006.1.4.409>.

- Moya-Álvarez, V., Quevedo-Marín, J.L., Ji, Z., Navarro-Jiménez, C., Jiménez-García, R., López-de-Andrés, A., Pérez-Trullén, A. dan de Miguel-Díez, J. (2020). Variation in Assignment of the COPD Patients into a GOLD Group According to Symptoms Severity. *International Journal of Chronic Obstructive Pulmonary Disease*, Volume 15, pp.1987–1995. doi:<https://doi.org/10.2147/copd.s253445>.
- Nair, Ns., Lakiang, T., Ramaswamy, A. dan Singhal, U. (2018). Economic impact of chronic obstructive pulmonary disease: A cross-sectional study at teaching hospital in South India. *Journal of Family Medicine and Primary Care*, 7(5), p.1002. doi:[https://doi.org/10.4103/jfmmpc.jfmmpc\\_75\\_16](https://doi.org/10.4103/jfmmpc.jfmmpc_75_16).
- Najafzadeh, M., Marra, C.A., Sadatsafavi, M., Aaron, S.D., Sullivan, S.D., Vandemheen, K.L., Jones, P.W. dan Fitzgerald, J.M. (2008). Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. *Thorax*, 63(11), pp.962–967. doi:<https://doi.org/10.1136/thx.2007.089557>.
- Naqvi, A. dan Gerriets, V. (2020). *Cetirizine*. [online] PubMed. Diakses melalui <https://www.ncbi.nlm.nih.gov/books/NBK549776/>.
- Nielsen, R., Kankaanranta, H., Bjermer, L., Lange, P., Arnetorp, S., Hedegaard, M., Stenling, A. dan Mittmann, N. (2013). Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. *Respiratory Medicine*, 107(11), pp.1709–1721. doi:<https://doi.org/10.1016/j.rmed.2013.06.007>.
- Nikmah, N.U. (2023). *Analisis Biaya dan Kesesuaian Biaya Riil terhadap Tarif INA-CBGs Pasien Penyakit Paru Obstruktif Kronis Peserta JKN Rawat Jalan di Rumah Sakit Akademik Universitas Gadjah Mada*. [online] [etd.repository.ugm.ac.id](http://etd.repository.ugm.ac.id). Diakses melalui : <https://etd.repository.ugm.ac.id/penelitian/detail/225818> [Diakses pada 5 April 2024].

- Oba, Y., Keeney, E., Ghatehorde, N., dan Dias, S. (2018). Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. *Cochrane Database of Systematic Reviews*. doi:<https://doi.org/10.1002/14651858.cd012620.pub2>.
- Özmen, B., Çelik, P., Yorgancioğlu, A., Özmen, B., Özmen, D. dan Çok, G. (2002). Pulmonary function parameters in patients with diabetes mellitus. *Diabetes Research and Clinical Practice*, 57(3), pp.209–211. doi:[https://doi.org/10.1016/s0168-8227\(02\)00057-8](https://doi.org/10.1016/s0168-8227(02)00057-8).
- Pauwels, Romain A., Buist, A. Sonia, Calverley, Peter M. A., Jenkins, Christine R., Hurd, dan Suzanne S. (2001). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. *American Journal of Respiratory and Critical Care Medicine*, [online] 163(5), pp.1256–1276. doi:<https://doi.org/10.1164/ajrccm.163.5.2101039>.
- PDPI. (2011). *Penyakit Paru Obstruktif Kronik : Pedoman Diagnosis dan Penatalaksanaan di Indonesia*, Perhimpunan Dokter Paru Indonesia, Jakarta.
- Peechakara, B.V. and Gupta, M. (2019). *Codeine*. [online] Nih.gov. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK526029/>.
- Poole, P., Sathananthan, K. dan Fortescue, R. (2019). Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*. doi:<https://doi.org/10.1002/14651858.cd001287.pub6>.
- Pray, W.S. dan Pray, G.E. (n.d.). *Respiratory Problems and Nonprescription Products*. [online] [www.uspharmacist.com](http://www.uspharmacist.com). <https://www.uspharmacist.com/article/respiratory-problems-and-nonprescription-products>.

- Price, D., Keininger, D., Costa-Scharplatz, M., Mezzi, K., Dimova, M., Asukai, Y. dan Ställberg, B. (2014). Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. *Respiratory Medicine*, [online] 108(12), pp.1786–1793. doi:<https://doi.org/10.1016/j.rmed.2014.09.015>.
- Rammeloo R.H.U., P.B. Luursema, Sips, A.P., Beumer, H.M., Wald, M. dan Cornelissen, G. (1992). Therapeutic Equivalence of a Fenoterol/Ipratropium Bromide Combination (Berodual) Inhaled as a Dry Powder and by Metered Dose Inhaler in Chronic Obstructive Airway Disease. *Respiration*, 59(6), pp.322–326. doi:<https://doi.org/10.1159/000196081>.
- Ramsey, S.D. dan Sullivan, S.D. (2003). The burden of illness and economic evaluation for COPD. *European Respiratory Journal*, 21(Supplement 41), pp.29S35s. doi:<https://doi.org/10.1183/09031936.03.00078203>.
- Remien, K. dan Bowman, A. (2022). *Fluticasone*. [online] PubMed. Diakses melalui : <https://www.ncbi.nlm.nih.gov/books/NBK542161/>.
- Restrepo, M.I., Sibila, O. dan Anzueto, A. (2018). Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. *Tuberculosis and Respiratory Diseases*, [online] 81(3), p.187. doi:<https://doi.org/10.4046/trd.2018.0030>.
- Riset Kesehatan Dasar (Riskesdas). (2013). *Badan Penelitian dan Pengembangan Kesehatan Kementerian RI tahun 2013*. Diakses: 19 September 2023, dari <http://www.depkes.go.id/resources/download/general/Hasil%20Riskesdas%20>
- Ronaldson, S.J., Raghunath, A., Torgerson, D.J. dan Van Staa, T. (2017). Cost-effectiveness of antibiotics for COPD management: observational analysis using CPRD data. *ERJ Open Research*, [online] 3(2), pp.00085-2016. doi:<https://doi.org/10.1183/23120541.00085-2016>.



- Ryan, M., Suaya, J.A., Chapman, J.D., Stason, W.B., Shepard, D.S. dan Parks Thomas, C. (2013). Incidence and Cost of Pneumonia in Older Adults with COPD in the United States. *PLoS ONE*, 8(10), p.e75887. doi:<https://doi.org/10.1371/journal.pone.0075887>.
- Shah, C.H., Reed, R.M., Wastila, L., Onukwugha, E., Gopalakrishnan, M. and Zafari, Z. (2023). Direct Medical Costs of COPD in the USA: An Analysis of the Medical Expenditure Panel Survey 2017-2018. *Applied Health Economics and Health Policy*, [online] 21(6), pp.915–924. doi:<https://doi.org/10.1007/s40258-023-00814-8>.
- Shujaat, A., Bajwa, A.A. dan Cury, J.D. (2012). Pulmonary Hypertension Secondary to COPD. *Pulmonary Medicine*, 2012, pp.1–16. doi:<https://doi.org/10.1155/2012/203952>.
- Silva, G.E., Sherrill, D.L., Guerra, S. dan Barbee, R.A. (2004). Asthma as a risk factor for COPD in a longitudinal study. *Chest*, [online] 126(1), pp.59–65. doi:<https://doi.org/10.1378/chest.126.1.59>.
- Soriano, J.B., Visick, G.T., Muellerova, H., Payvandi, N. dan Hansell, A.L. (2005). Patterns of Comorbidities in Newly Diagnosed COPD and Asthma in Primary Care. *Chest*, 128(4), pp.2099–2107. doi:<https://doi.org/10.1378/chest.128.4.2099>.
- Strategy for the Diagnosis, Management, and Prevention of COPD (2018 Report)*.  
Diakses dari : <http://www.goldcopd.org>, diakses pada September 2023
- Stuart, B.C., Simoni-Wastila, L., Zuckerman, I.H., Davidoff, A., Shaffer, T., Yang, H.K., Qian, J., Dalal, A.A., Mapel, D.W. dan Bryant-Comstock, L. (2010). Impact of maintenance therapy on hospitalization and expenditures for Medicare beneficiaries with chronic obstructive pulmonary disease. *The American Journal of Geriatric Pharmacotherapy*, [online] 8(5), pp.441–453. doi:<https://doi.org/10.1016/j.amjopharm.2010.10.002>.

- Szafranski, W., Cukier, A., Ramirez, A., Menga, G., Sansores, R., Nahabedian, S., Peterson, S. dan Olsson, H. (2003). Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. *European Respiratory Journal*, 21(1), pp.74–81. doi:<https://doi.org/10.1183/09031936.03.00031402>.
- Tashkin, D.P. (2020). Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease. *International Journal of Chronic Obstructive Pulmonary Disease*, Volume 15, pp.3105–3122. doi:<https://doi.org/10.2147/copd.s273497>.
- Tashkin, D.P., Lipworth, B. dan Brattsand, R. (2019). Benefit:Risk Profile of Budesonide in Obstructive Airways Disease. *Drugs*, [online] 79(16), pp.1757–1775. doi:<https://doi.org/10.1007/s40265-019-01198-7>.
- Thanh T.N. Phan, Van Giap Vu, Le-Thi Tuyet-Lan, Viet Nhung Nguyen dan Ngo Quy Chau (2023). Medication Adherence Assessment and Cost Analysis of COPD Treatment Under Out-Patient Clinic in Vietnam. *Health services insights*, 16, p.117863292311775-117863292311775. doi:<https://doi.org/10.1177/11786329231177545>.
- Tonin, F.S., Aznar-Lou, I., Pontinha, V.M., Pontarolo, R. dan Fernandez-Llimos, F. (2021). Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. *Pharmacy Practice*, 19(1), p.2302. doi:<https://doi.org/10.18549/pharmpract.2021.1.2302>.
- Torabipour, A., Hakim, A., Kambiz Ahmadi Angali, Marzieh Dolatshah dan Yusofzadeh, M. (2016). Cost Analysis of Hospitalized Patients with Chronic Obstructive Pulmonary Disease: A State-Level Cross-Sectional Study. *PubMed*, 15(2), pp.75–82.
- Trigueros, J.A., Garin, N., Baloiira, A., Aceituno, S., Calvo, A., Prades, M., Tournon, C., Martínez, A. dan Torres, C. (2022). Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary

Disease in Spain. *International Journal of Chronic Obstructive Pulmonary Disease*, Volume 17, pp.2905–2917.  
doi:<https://doi.org/10.2147/copd.s384591>.

Tsai, M.-J., Chen, C.-Y., Huang, Y.-B., Chao, H.-C., Yang, C.-J., Lin, P.-C. and Tsai, Y.-H. (2015). Long-acting Inhaled Bronchodilator and Risk of Vascular Events in Patients With Chronic Obstructive Pulmonary Disease in Taiwan Population. *Medicine*, 94(51), p.e2306.  
doi:<https://doi.org/10.1097/md.0000000000002306>.

Tse, H.N., Raiteri, L., Wong, K.Y., Yee, K.S., Ng, L.Y., Wai, K.Y., Loo, C.K. dan Chan, M.H. (2013). High-Dose N-Acetylcysteine in Stable COPD. *Chest*, 144(1), pp.106–118. doi:<https://doi.org/10.1378/chest.12-2357>.

Tzanakis, N., Hillas, G., Perlikos, F. dan Tsiligianni, I. (2015). Managing Comorbidities in COPD. *International Journal of Chronic Obstructive Pulmonary Disease*, 10(10), p.95. doi:<https://doi.org/10.2147/copd.s54473>.

Van Eerd, E.A., van der Meer, R.M., van Schayck, O.C. dan Kotz, D. (2016). Smoking cessation for people with chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*, [online] 2016(8). doi:<https://doi.org/10.1002/14651858.cd010744.pub2>.

Varmaghani, M., Dehghani, M., Heidari, E., Sharifi, F., Saeedi Moghaddam, S. dan Farzadfar, F. (2019). Global prevalence of chronic obstructive pulmonary disease: systematic review and meta-analysis. *Eastern Mediterranean Health Journal*, [online] 25(1), pp.47–57. doi:<https://doi.org/10.26719/emhj.18.014>.

Vo, T.Q., Phung, T.C.N., Vu, T.Q., Tran, T.N., Vo, T.T.T., PHAN, V.H.A. dan Pham, L.D. (2018). Cost Trend Analysis of Chronic Obstructive Pulmonary Disease among Vietnamese Patients: Findings from Two Provincial

Facilities 2015–2017. *JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH*. doi:<https://doi.org/10.7860/jcdr/2018/36668.11715>.

Wacker, M., Kitzing, K., Jörres, R., Leidl, R., Schulz, H., Karrasch, S., Karch, A., Koch, A., Vogelmeier, C. dan Holle, R. (2017). The Contribution of Symptoms and Comorbidities To The Economic Impact of COPD: an analysis of the German COSYCONET cohort. *International Journal of Chronic Obstructive Pulmonary Disease*, Volume 12, pp.3437–3448. doi:<https://doi.org/10.2147/copd.s141852>.

Welte, T., Miravitlles, M., Hernandez, P., Eriksson, G., Peterson, S., Polanowski, T. dan Kessler, R. (2009). Efficacy and Tolerability of Budesonide/Formoterol Added to Tiotropium in Patients with Chronic Obstructive Pulmonary Disease. *American Journal of Respiratory and Critical Care Medicine*, 180(8), pp.741–750. doi:<https://doi.org/10.1164/rccm.200904-0492oc>.

World Health Organization (2023). *Chronic obstructive pulmonary disease (COPD)*. [online] World Health Organization: WHO. Diakses melalui : [https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-\(copd\)](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd))

Wu, W., Awab, A. dan Metcalf, J.P. (2014). N-Acetylcysteine Protection in COPD. *Chest*, 145(1), pp.193–194. doi:<https://doi.org/10.1378/chest.13-2029>.

Yawn BP, Raphiou I, Hurley JS, dan Dalal AA. (2010). The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. *International Journal of Chronic Obstructive Pulmonary Disease*, p.165. doi:<https://doi.org/10.2147/copd.s4159>.

Zhang, L., Liu, Y., Zhao, S., Wang, Z., Zhang, M., Zhang, S., Wang, X., Zhang, S., Zhang, W., Hao, L. dan Jiao, G. (2022). The Incidence and Prevalence of Pulmonary Hypertension in the COPD Population: A Systematic Review

and Meta-Analysis. *International Journal of Chronic Obstructive Pulmonary Disease*, Volume 17, pp.1365–1379.  
doi:<https://doi.org/10.2147/copd.s359873>.